Search results
3 dni temu · Berlin, September 27, 2024 – Bayer announced today that new subgroup analyses from the Phase III FINEARTS-HF trial evaluating finerenone (Kerendia™) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥ 40% will be presented at the Heart Failure Society of America (HFSA) Annual Meeting 2024.. Data being presented at HFSA include:
20 wrz 2024 · Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with a common form of heart failure with high unmet medical need. Finerenone is the first non-steroidal mineralocorticoid receptor (MR) antagonist to demonstrate definitive benefits in its primary composite endpoint versus placebo in a Phase III study ...
5 sie 2024 · Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. By targeting MR and renin-angiotensin-aldosterone system (RAAS) overactivation, finerenone addresses hallmarks of HF with a LVEF ≥40%, such as progressive fibrosis.
In this webinar from SCI's Fine Chemicals Group and Young Chemists' Panel, Dr Lars Bärfacker discusses the development of dihydronaphthyridine finerenone, a therapeutic for counteracting negative...
1 wrz 2024 · Based on the results of FINEARTS-HF, finerenone is the first MR antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with this common form of heart failure. The FINEARTS-HF findings were presented today during a Hot Line session at ESC Congress 2024 and simultaneously published in the New England Journal ...
2 wrz 2024 · Bayer plans to submit applications to health authorities for marketing authorization for finerenone for an indication in heart failure with a LVEF of ≥40%.
5 sie 2024 · Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with...
